Agilent Technologies announces more than one million bioanalyzer chips sold

PALO ALTO, Calif., Oct. 5, 2004

Agilent Technologies Inc. (NYSE: A) today announced that it has sold more than one million LabChip(r) chips -- small, analytical devices used with the Agilent 2100 bioanalyzer to perform fast, automated analysis of DNA, RNA, proteins and cells. These chips are based on lab-on-a-chip technology, which relies on the principles of microfluidics to manipulate tiny amounts of liquid within a miniaturized system.

"Scientists recognize the benefits of lab-on-a-chip technology for improving speed, data quality and ease of use," said Tony Owen, liquid phase analysis platform marketing manager for Agilent's Pharmaceutical Analysis business. "They are making extensive use of our technology in their peer-reviewed research, as seen in the more than 1,000 citations for the bioanalyzer in scientific literature."

In collaboration with Caliper Life Sciences, Inc., Agilent introduced the industry's first commercial lab-on-a-chip system, the Agilent 2100 bioanalyzer, in 1999. With more than 2,500 sold, the bioanalyzer has become a valuable tool for genomics, proteomics, biopharmaceutical development and manufacturing, food safety and homeland security. In genomics, the bioanalyzer has become an industry-standard platform for RNA quality assessment in gene expression, polymerase chain reaction and RNA interference experiments.

Lab-on-a-chip technology offers several advantages over gel electrophoresis, one of the oldest and most widely used techniques in the life sciences. In gel electrophoresis, nucleic acids or proteins are manually loaded into a gel matrix that separates molecules by size, charge and/or shape when an electric field is applied.

The bioanalyzer integrates and automates this process, resulting in smaller sample use, faster analyses and more accurate and reproducible results. For some protein analyses, the bioanalyzer can reduce total turnaround time 20-fold compared with gel electrophoresis. In addition, the bioanalyzer can be modified for regulatory-compliant use in pharmaceutical environments.

To standardize RNA quality measurement using the bioanalyzer, Agilent introduced a beta version of its RNA integrity number (RIN) software earlier this year. RIN is the first tool for objectively grading and communicating the quality of RNA used in experiments. It is designed to improve the reproducibility and comparison of RNA-based research data and to facilitate the submission of data for review by the U.S. Food and Drug Administration.

Later this year, the company expects to release the first fully automated, high-throughput lab-on-a-chip system, which will enable unattended analysis of thousands of DNA or protein samples per day.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global technology leader in communications, electronics, life sciences and chemical analysis. The company's 28,000 employees serve customers in more than 110 countries. Agilent had net revenue of $6.1 billion in fiscal year 2003. Information about Agilent is available on the Web at

# # #

LabChip is a registered trademark of Caliper Life Sciences, Inc., in the U.S. and other countries.


Christina Maehr
+1 408 553 7205